A parliamentary committee urges the government to broaden price controls on cancer drugs, encompassing vaccines, immunotherapy, and oral chemotherapy, citing that many medications remain unaffordable due to regulatory gaps. The committee also emphasizes the need for stringent quality monitoring of generic drugs to encourage their prescription by medical professionals, addressing existing hesitancy.
